| Description |
1 online resource (302 pages). |
| Physical Medium |
polychrome |
| Description |
text file |
| Series |
ISSN
|
|
ISSN.
|
| Note |
Description based upon print version of record. |
| Contents |
Intro -- Title -- Copyright -- Contents -- Chapter 1 Overview of Antiviral Drug Discovery and Development: Viral Versus Host Targets -- 1.1 Introduction -- 1.2 Viral Targets for Antiviral Drugs -- 1.2.1 Viral Polymerases -- 1.2.2 Viral Integrase -- 1.2.3 Viral Proteases -- 1.2.4 Structural Proteins -- 1.2.5 Accessory Proteins -- 1.3 Host Targets for Antiviral Drugs -- 1.3.1 Host Chemokine Receptors -- 1.3.2 Host Glycoproteins -- 1.3.3 Host Kinases -- 1.3.4 Other Host Proteins -- 1.4 Viral Versus Host Targets -- 1.4.1 Strengths and Weaknesses of Viral Targets |
|
1.4.2 Strengths and Weaknesses of Host Targets -- 1.5 Conclusion -- Conflicts of Interest -- Acknowledgements -- References -- Chapter 2 Advances in Prophylaxis and Therapy of Arenavirus Hemorrhagic Fevers -- 2.1 Introduction -- 2.2 Therapeutic Approaches Against Arenaviruses -- 2.2.1 Immunotherapeutic Approaches -- 2.2.2 Antivirals -- 2.3 Prophylaxis of Arenavirus Infections -- 2.4 Concluding Remarks -- References -- Chapter 3 Vaccines and Antiviral Developments for SARS-CoV-2 in the Emergence of the COVID-19 Pandemic1 -- 3.1 Origin of the COVID-19 Pandemic Produced by SARS-CoV-2 |
|
3.2 Coronavirus and Zoonotic Risk -- 3.3 Human Coronaviruses -- 3.4 Structure and Genomic Organization of SARS-CoV-2 -- 3.5 Mechanism of Infection and Pathogenesis of SARS-CoV-2 -- 3.6 Diagnosis and Kinetics of Respiratory Infection by SARS-CoV-2 -- 3.7 The Immune Response to SARS-CoV-2 -- 3.8 Vaccine Development for COVID-19 -- 3.9 Monoclonal Antibodies Against SARS-CoV-2 for COVID-19 Treatment -- 3.10 Antiviral Development for SARS-CoV-2/COVID-19 -- References -- Chapter 4 Small-molecule and Synthetically Derived Antivirals for Ebola Virus and Other Filoviruses1 -- 4.1 Introduction |
|
Chapter 5 Antiviral Strategies for Ebola Virus and Other Filoviruses: Antibodies -- 5.1 Introduction -- 5.2 Introduction to Filoviruses -- 5.2.1 Role of Abs in Natural Infection -- 5.2.2 Role of Abs in Understanding Outbreaks -- 5.2.3 Antibody-dependent Enhancement -- 5.3 The Role of Abs Generated by Experimental Vaccines -- 5.4 Development of Antibodies for Filovirus Medical Countermeasures -- 5.4.1 EBOV mAb Countermeasures -- 5.4.2 Non-EBOV Filoviruses and pan-Ebolavirus mAbs in NHPs |
| Note |
5.4.3 Clinical Evaluation of Passive Immunization during the 2013-2016 West Africa Outbreak and the 2018-2020 DRC Outbreak. |
| Summary |
Ideal for drug discovery scientists and medicinal chemists with an interest in antiviral drug discovery and development, this book provides a complete overview of the latest progress in the field, recent advances and the challenges that remain in developing these highly pathogenic agents. |
| Local Note |
eBooks on EBSCOhost EBSCO eBook Subscription Academic Collection - North America |
| Subject |
Antiviral agents.
|
|
Antiviral agents. |
| Genre/Form |
Electronic books.
|
| Added Author |
Delgado, Rafael.
|
| Other Form: |
Print version: Muñoz-Fontela, César Antiviral Discovery for Highly Pathogenic Emerging Viruses Cambridge : Royal Society of Chemistry,c2021 9781788015646 |
| ISBN |
1839160535 |
|
9781839160530 (electronic book) |
|
